Searchable abstracts of presentations at key conferences in endocrinology

ea0087p9 | Poster Presentations | UKINETS2022

Ocular neuroendocrine tumour metastases – presentation & outcome

Shah Husnain , Roji Mohamad , Ekmekcioglu Ozgul , Ayuk John , Smith Stacey , Khan Zaira , Vickrage Suzanne , Kemp-Blake Joanne , Humphries Sian , Hughes Simon , Diaz-Cano Salvador , Elshafie Mona , Karkhanis Salil , Shetty Shishir , Geh Ian , Shah Tahir

Introduction: Here we present our experience of managing patients with orbital well-differentiated neuroendocrine tumour (NET) metastases.Methods: Six patients were identified from the hospital NET database: four male; two female.Results: Median age at diagnosis of primary NET: 69.5 years (range: 40-74 years). Three patients were alive at time of data capture. Of those who passed away: mean survival from diagnosis of primary NET = ...

ea0072p4 | (1) | UKINETS2020

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Khanna Amardeep , Cianci Nicole , Abbas Shah Husnain , Goel Ashish , Jebril Asma , Chauhan Jessica , Pipe Michelle , Shetty Shishir , Weston Christopher , Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Shah Tahir

Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze and can be challenging to manage. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase 3 clinical trials but la...

ea0072p13 | (1) | UKINETS2020

Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

Lithgow Kirstie , Venkataraman Hema , Hughes Simon , Shah Husnain , Kemp-Blake Joanne , Vickrage Suzanne , Smith Stacey , Humphries Sian , Elshafie Mona , Taniere Philipe , Diaz-Cano Salvador , Dasari Bobby , Almond Max , Ford Sam , Ayuk John , Shetty Shishir , Shah Tahir , Geh Ian

Purpose: Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67>20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC). Clinical management of NET G3 is challenging due to limited data to inform treatment strategies.Methods: We describe clinical characteristics, treatment, an...

ea0077p211 | Neuroendocrinology and Pituitary | SFEBES2021

Digital transformation of a hyponatraemia toolkit: impact on clinical practice

Zeeshan Amna , Devendra Senan , O’Dowd Christina , Shah Pooja , Goodka Roshni , Devendra Ruben , Obaidee Sayed , Patel Bharat

Hyponatraemia is associated with an increased morbidity and mortality. Despite having a hyponatraemia algorithm (pdf format) on our hospital intranet, it was rarely accessed and a wide variation in care was noticed. A novel digital hyponatraemia diagnostic toolkit (hyponatraemia.wordpress.com) for Foundation doctors (FDs) was introduced to assess our aims if it: A) increases the awareness of FDs to start investigating when serum Sodium is <130 mmol/l B) increases FD...

ea0077p237 | Reproductive Endocrinology | SFEBES2021

Impact of pharmacological Interventions on androgen hormones in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials

Abdalla Mohammed , Shah Najeeb , Deshmukh Harshal , Sahebkar Amirhossein , Ostlundh Linda , Al-Rifai Rami H , Atkin Stephen L , Sathyapalan Thozhukat

Context: Polycystic ovary syndrome (PCOS) is a complex endocrine disease that affects women of reproductive age and characterised by biochemical and clinical androgen excess.Aim: To review the available literature on the effectiveness of the various pharmacological interventions on androgen hormones in women with PCOS.Data source: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane library and the Web of Science in April 2020 and...

ea0077p240 | Reproductive Endocrinology | SFEBES2021

Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: a systematic review and meta-analysis

Abdalla Mohammed , Shah Najeeb , Deshmukh Harshal , Sahebkar Amirhossein , Ostlundh Linda , Al-Rifai Rami H. , Atkin Stephen L , Sathyapalan Thozhukat

Context: Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of reproductive age. It is associated with dyslipidaemia and elevated plasma C-reactive protein (CRP), which increase the risks of cardiovascular disease (CVD).Objective: To review the existing evidence on the effects of different pharmacological interventions on lipid profiles of women with PCOS.Data sources: We searched PubMed, MEDLINE, Scopus,...

ea0078OC9.3 | Oral Communications 9 | BSPED2021

Investigating paediatric weight management apps

Ayamad Sithara , Mohebi Mustafa , Sarathchandra Nichola Rowena , Shah Pratik , Desai Ashish , Gevers Evelien , Peh Gin , Ford-Adams Martha , Chan Li

Background: Childhood obesity is the single most pressing public health emergency of the 21st century. The prevalence has increased at alarming rates and globally over 41 million children under 5 years of age are classified as overweight/obese. Overweight and obese children are likely to stay obese as adults and develop multi-morbidities including type 2 diabetes, cancer, non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease at an earlier age. The ava...

ea0052p23 | (1) | UKINETS2017

Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Banks Jamie , Shah Ruchir , Smith Jack , Jacobs Ben , Galanopoulos Michalis , Caplin Martyn , Mandair Dalvinder , Toumpanakis Christos

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

ea0052p24 | (1) | UKINETS2017

Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Shah Ruchir , Banks Jamie , Jacobs Ben , Smith Jack , Galanopoulos Michalis , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Escalated doses of octreotide LAR are commonly used to control functional symptoms and/or tumour growth, but there is limited evidence regarding the efficacy of this approach.Methods: Retrospective analysis of 69 NET patients treated with octreotide LAR 30 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change in symptomatology and biomarker levels was considered significant....

ea0051p038 | Pituitary and growth | BSPED2017

Growth hormone neurosecretory dysfunction as part of the spectrum of growth hormone deficiency disorders which benefit from growth hormone treatment

Caiulo Silvana , Gan Hoong-Wei , Hughes Claire R. , Amin Rakesh , Spoudeas Helen , Peters Catherine , Hindmarsh Peter , Shah Pratik , Dattani Mehul

Objectives: Current provocative tests for GH deficiency (GHD) are neither 100% sensitive nor specific. GH neurosecretory dysfunction (NSD) refers to the presence of growth failure, normal stimulated GH responses, but impaired spontaneous GH secretion. We describe our experience in managing GHNSD over 7 years.Methods: We retrospectively reviewed a cohort of 106 children admitted for 12-h overnight GH profiles (with 20-min sampling) between 2010 and 2016. ...